Brief: Neurogene Announces Expansion, Plans For More Rapid Patient Enrollment Of Rett Syndrome Gene Therapy Clinical Trial

Neurogene

04/03/2024 12:42

March 4 (Reuters) - Neurogene Inc  NGNE.O :
    * NEUROGENE ANNOUNCES EXPANSION AND PLANS FOR MORE RAPID
PATIENT
ENROLLMENT OF RETT SYNDROME GENE THERAPY CLINICAL TRIAL
    * NEUROGENE INC - ONGOING PHASE 1/2 CLINICAL TRIAL FOR
NGN-401 TO
INCLUDE ADDITIONAL PATIENTS IN COHORT 1 AND A DOSE-ESCALATION
COHORT
    * NEUROGENE INC - REMOVAL OF STAGGERED DOSING IN COHORT 1
EXPECTED
TO ENABLE ANTICIPATED COMPLETION OF COHORT 1 DOSING IN SECOND
HALF OF 2024
    * NEUROGENE INC - FIRST THREE PATIENTS IN COHORT 2 WILL BE
DOSED
IN A STAGGERED MANNER, WITH FIRST PATIENT DOSING EXPECTED IN Q2
OF 2024
    * NEUROGENE INC - REMAINS ON TRACK TO REPORT INTERIM
CLINICAL DATA
FROM COHORT 1 IN Q4 2024,ADDITIONAL DATA, INCLUDING FROM COHORT
2, IN H2 OF 2025

Source text for Eikon:  ID:nBw1GkzrMa 
Further company coverage:  NGNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))